%0 Journal Article
%T Efficacy of Adjuvant Sublingual Immunotherapy After Septomeatoplasty.
%A Hsieh BH
%A Kuo YC
%A Yong SB
%A Tien HC
%A Hsu CC
%A Hsu CL
%A Tsou YA
%A Lin CD
%A Tai CJ
%A Wang JY
%A Shih LC
%J Laryngoscope
%V 134
%N 7
%D 2024 Jul 19
%M 38372411
%F 2.97
%R 10.1002/lary.31347
%X <B>BACKGROUND: </B>The efficacy of adjuvant sublingual immunotherapy (SLIT) in correcting structural problems in patients with allergic rhinitis (AR) caused by mite who have undergone septomeatoplasty (SMP) has not been studied.<BR><B>METHODS: </B>This non-randomized controlled study recruited patients with AR (caused by mite) and concurrent septal deviation and inferior turbinate hypertrophy, at a tertiary hospital in Taiwan. SMP was performed on all patients as a surgical intervention. The patients were then divided into two groups: the control group, which underwent surgery only, and the experimental group, which received SLIT as an adjuvant treatment. Demographic data and rhinitis control assessment test (RCAT) results were analyzed.<BR><B>RESULTS: </B>A total of 96 patients were enrolled in the study (SMP + SLIT group, n = 52; SMP only group, n = 44). No significant differences were observed in any of the variables between the two groups before and one month after surgery. However, during evaluations at the third and sixth month, the SMP + SLIT group showed significant improvement in the total RCAT scores compared to the SMP only group (28.6 ± 1.56 vs. 24.5 ± 3.66, p < 0.001; 27.1 ± 2.87 vs. 19.9 ± 5.56, p < 0.001). In addition, significantly better control of all RCAT sub-categories was observed in the SMP + SLIT group at the third and sixth month evaluations.<BR><B>CONCLUSIONS: </B>SLIT may serve as an ideal adjuvant therapy after SMP in patients with AR.<BR><B>METHODS: </B>3 Laryngoscope, 134:3073-3079, 2024.